Reata Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Reata Pharmaceuticals has a total shareholder equity of $87.3M and total debt of $73.1M, which brings its debt-to-equity ratio to 83.8%. Its total assets and total liabilities are $502.6M and $415.3M respectively.
Key information
83.8%
Debt to equity ratio
US$73.13m
Debt
Interest coverage ratio | n/a |
Cash | US$330.21m |
Equity | US$87.29m |
Total liabilities | US$415.30m |
Total assets | US$502.59m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2R3's short term assets ($401.8M) exceed its short term liabilities ($125.1M).
Long Term Liabilities: 2R3's short term assets ($401.8M) exceed its long term liabilities ($290.2M).
Debt to Equity History and Analysis
Debt Level: 2R3 has more cash than its total debt.
Reducing Debt: 2R3 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2R3 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2R3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.